CPAP and non-small cell lung carcinoma: MTT assays have shown that Caerin 1.1 is taken up by CAL-62 and B-CPAP cells and is mainly enriched in the cytoplasm (23), suggesting that Caerin 1.1 and Caerin 1.9 can also be taken up by NSCLC (A549) cells to exert an inhibitory effect.